Deltex Medical ( (GB:DEMG) ) has provided an announcement.
Deltex Medical Group PLC announced that its shareholders approved a resolution to cancel the trading of its ordinary shares on the AIM market. The cancellation will take effect on February 21, 2025, with a Matched Bargain Facility organized to facilitate share transactions post-cancellation. While this facility will allow trading for at least 12 months, the liquidity and marketability of shares remain uncertain. This strategic move reflects an operational shift, possibly to focus on new advancements and market opportunities, such as its non-invasive monitoring technology, which could significantly impact its industry positioning.
More about Deltex Medical
Deltex Medical Group PLC is a company in the medical technology industry, specializing in haemodynamic monitoring technologies. Their primary product, the TrueVue System, utilizes proprietary technology to improve patient outcomes and hospital efficiency. The company focuses on expanding the application of its technologies across various healthcare settings, including operating theaters and ICUs, with recent developments in non-invasive monitoring broadening their market reach. Deltex Medical sells directly to the NHS in the UK and various hospital systems in the USA, as well as through distributors in over 40 countries.
YTD Price Performance: -60.0%
Average Trading Volume: 15,555,194
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £616.2K
For an in-depth examination of DEMG stock, go to TipRanks’ Stock Analysis page.